
Boston Scientific beats Q2 estimates but lowers 2026 outlook amid competition, stock target cut to $70
Boston Scientific reported strong Q2 results with revenue of $5.442 billion and adjusted EPS of $0.86, surpassing analyst expectations. However, RBC Capital lowered the 2026 stock price target from $85 to $70 due to competitive pressures and a reduce...

